Search clinical trials for: Relmada

Total 9 results

Relmada Therapeutics, Inc.

Recruiting

Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD (RELIGHT)

Depression | Major Depressive Disorder

United States
Relmada Therapeutics, Inc.

Recruiting

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (RELIANCE-II)

Depression | Major Depressive Disorder

United States
Relmada Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) (Reliance III)

Major Depressive Disorder

United States
Relmada Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (Reliance I)

Major Depressive Disorder

United States
Relmada Therapeutics, Inc.

Completed

Safety of REL-1017 for Major Depressive Disorder (RELIANCE-OLS)

Major Depressive Disorder

United States
Relmada Therapeutics, Inc.
Syneos Health

Completed

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

Depressive Disorder, Major | Depressive Disorder, Treatment-Resistant

United States
Relmada Therapeutics, Inc.

Available

REL-1017 Expanded Access Treatment

Depression | Major Depressive Disorder
Relmada Therapeutics, Inc.

Completed

Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)

Neuropathic Pain
Relmada Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)

Neuropathic Pain

3

Subscribe